Autonomix Medical Files 8-K
Ticker: AMIX · Form: 8-K · Filed: Aug 27, 2025 · CIK: 1617867
Sentiment: neutral
Topics: 8-k, regulatory-filing
TL;DR
Autonomix Medical filed an 8-K on 8/27 for events on 8/25. Standard disclosure.
AI Summary
Autonomix Medical, Inc. filed an 8-K on August 27, 2025, reporting other events and financial statements as of August 25, 2025. The filing does not detail specific transactions or events but serves as a notification of these items.
Why It Matters
This 8-K filing indicates Autonomix Medical, Inc. is providing updates or disclosures to the SEC, which could be relevant for investors monitoring the company's regulatory compliance and corporate actions.
Risk Assessment
Risk Level: low — The filing is a standard 8-K for 'Other Events' and 'Financial Statements and Exhibits' without specific material disclosures, indicating routine regulatory compliance.
Key Players & Entities
- Autonomix Medical, Inc. (company) — Registrant
- August 25, 2025 (date) — Date of earliest event reported
- August 27, 2025 (date) — Date of report
- Delaware (jurisdiction) — State of incorporation
- 713-588-6150 (phone_number) — Registrant's telephone number
- 21 Waterway Avenue, Suite 300 (address) — Principal executive offices
- The Woodlands, TX 77380 (address) — Principal executive offices
FAQ
What specific 'Other Events' are being reported by Autonomix Medical, Inc. in this 8-K filing?
The filing indicates 'Other Events' are being reported, but the specific details of these events are not provided in the provided text excerpt.
When was the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing was on August 25, 2025.
What is the principal executive office address for Autonomix Medical, Inc.?
The principal executive office address for Autonomix Medical, Inc. is 21 Waterway Avenue, Suite 300, The Woodlands, TX 77380.
What is the registrant's telephone number?
The registrant's telephone number is (713) 588-6150.
What is the Standard Industrial Classification code for Autonomix Medical, Inc.?
The Standard Industrial Classification code for Autonomix Medical, Inc. is 3841, which corresponds to SURGICAL & MEDICAL INSTRUMENTS & APPARATUS.
Filing Stats: 592 words · 2 min read · ~2 pages · Grade level 9.2 · Accepted 2025-08-27 17:16:15
Key Financial Figures
- $0.001 — h Registered Common Stock , par value $0.001 per share AMIX The Nasdaq Stock Mark
- $2.1 million — initial aggregate sales price of up to $2.1 million (the "Shares"). On August 25, 2025, the
- $1.4 million — that may be sold under the Agreement by $1.4 million. Any sale of Shares pursuant to the Ag
Filing Documents
- amix20250827_8k.htm (8-K) — 28KB
- ex_857576.htm (EX-5.1) — 17KB
- image1.jpg (GRAPHIC) — 6KB
- image2.jpg (GRAPHIC) — 2KB
- 0001437749-25-027890.txt ( ) — 195KB
- amix-20250825.xsd (EX-101.SCH) — 3KB
- amix-20250825_def.xml (EX-101.DEF) — 12KB
- amix-20250825_lab.xml (EX-101.LAB) — 15KB
- amix-20250825_pre.xml (EX-101.PRE) — 12KB
- amix20250827_8k_htm.xml (XML) — 3KB
01. Other Events
Item 8.01. Other Events. As previously reported, on July 26, 2024, Autonomix Medical, Inc. (the "Company") entered into an At Market Issuances Sales Agreement (the "Agreement") with Ladenburg Thalmann & Co. Inc. (the "Agent"). Pursuant to the terms of the Agreement, the Company may sell from time to time through the Agent, as sales agent or principal, shares of the Company's common stock, par value $0.001 per share with an initial aggregate sales price of up to $2.1 million (the "Shares"). On August 25, 2025, the Company increased the aggregate sales price of Shares that may be sold under the Agreement by $1.4 million. Any sale of Shares pursuant to the Agreement will be made under the Company's effective "shelf" registration statement on Form S-3 (File No. 333-285464), which became effective on March 11, 2025 and includes a base prospectus, and under the related prospectus supplement filed with the Securities and Exchange Commission on August 25, 2025.
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits. (d) Exhibits No. Description 1.1 At Market Issuance Sales Agreement, dated February 28, 2025, by and between Autonomix Medical, Inc. and Ladenburg Thalmann & Co. Inc. (incorporated by reference to exhibit 1.1 of the Form 8-K filed February 28, 2025) 5.1 Opinion of ArentFox Schiff LLP 23.1 Consent of ArentFox Schiff LLP (included in Exhibit 5.1) 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) Signature Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. AUTONOMIX MEDICAL, INC. By: /s/ Trent Smith Trent Smith Chief Financial Officer Dated: August 27, 2025